Case Page


Case Status:    ONGOING    
On or around 12/04/2017 (Ongoing date of last review)

Filing Date: August 18, 2017

According to the law firm press release, Endo International PLC ("Endo") is a Global specialty healthcare company focused on branded and generic pharmaceuticals and devices. Endo has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, Pennsylvania. Endo commenced operations in 1997 by acquiring certain pharmaceutical products, related rights and assets from The DuPont Merck Pharmaceutical Company. Since that time, the Company has expanded to include the following business segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. Endo employs approximately 4,900 people worldwide.

One of the Company's branded pharmaceuticals is Opana ER ("Opana"), an opioid analgesic indicated for the management of severe pain that requires daily opioid treatment and for which alternative treatment options are ineffective.

The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.


Sector: Healthcare
Industry: Major Drugs
Headquarters: Ireland


Ticker Symbol: ENDP
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: E.D. Pennsylvania
DOCKET #: 17-CV-03711
JUDGE: Hon. Timothy J. Savage
DATE FILED: 08/18/2017
CLASS PERIOD END: 07/06/2017
  1. Levi & Korsinsky LLP (DC)
    1101 30th Street, NW; Suite 115, Levi & Korsinsky LLP (DC), DC 20007
  2. O'Kelly Ernst & Joyce, LLC
    901 N. Market Street, Suite 1000, O'Kelly Ernst & Joyce, LLC, DE
No Document Title Filing Date